Changchun Huayang High-tech Co., Ltd   Report issue

For profit Phase 3
Founded: Changchun China (2002)
Status: No NME R&D (2002)

Organization Overview

First Clinical Trial
2011
NCT01569516
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Changchun Huayang High-tech Co., Ltd

Active Ingredients

Drugs in Phase 3 Trials (2)

donepezil (aricept) (1 trial)

octohydroaminoacridine (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2